CLINICAL TRIALS PROFILE FOR RAPASTINEL

Clinical Trials for Rapastinel

Trial ID	Title	Status	Sponsor	Phase	Summary
NCT02192099 ↗	Open Label Extension for GLYX13-C-202, NCT01684163	Terminated	Naurex, Inc	Phase 2	Examine the safety of long term repeat exposure to GLYX-13 in subjects who participated in GLYX13-C-202.
NCT02192099 ↗	Open Label Extension for GLYX13-C-202, NCT01684163	Terminated	Naurex, Inc, an affiliate of Allergan plc	Phase 2	Examine the safety of long term repeat exposure to GLYX-13 in subjects who participated in GLYX13-C-202.
NCT02267629 ↗	Open Label Trial of Rapastinel (Formerly GLYX-13) in Individuals With Obsessive-Compulsive Disorder	Completed	New York State Psychiatric Institute	Phase 2	This research study tests whether GLYX-13 - an experimental drug that acts on a brain receptor called NMDA - can decrease symptoms of OCD within hours. This is not a treatment study. Results from this study will allow doctors and researchers to better understand if you and others with OCD may respond to a class of medications that target the NMDA brain receptor.
NCT02932943 ↗	A Study of Rapastinel as Adjunctive Therapy in Major Depressive Disorder (RAP-MD-01)	Completed	Allergan	Phase 3	This study will evaluate the efficacy, safety, and tolerability of rapastinel 450 mg compared to placebo adjunctive to antidepressant therapy (ADT) in patients with major depressive disorder (MDD) who have a partial response to ADT.
NCT02932943 ↗	A Study of Rapastinel as Adjunctive Therapy in Major Depressive Disorder (RAP-MD-01)	Completed	Naurex, Inc, an affiliate of Allergan plc	Phase 3	This study will evaluate the efficacy, safety, and tolerability of rapastinel 450 mg compared to placebo adjunctive to antidepressant therapy (ADT) in patients with major depressive disorder (MDD) who have a partial response to ADT.
NCT02943564 ↗	A Study of Rapastinel as Adjunctive Therapy in Major Depressive Disorder (RAP-MD-02)	Completed	Allergan	Phase 3	This study will evaluate the efficacy, safety, and tolerability of two doses of rapastinel, 225 milligrams (mg) and 450 mg, compared to placebo adjunctive to antidepressant therapy (ADT) in patients with major depressive disorder (MDD) who have a partial response to ADT.
NCT02943564 ↗	A Study of Rapastinel as Adjunctive Therapy in Major Depressive Disorder (RAP-MD-02)	Completed	Naurex, Inc, an affiliate of Allergan plc	Phase 3	This study will evaluate the efficacy, safety, and tolerability of two doses of rapastinel, 225 milligrams (mg) and 450 mg, compared to placebo adjunctive to antidepressant therapy (ADT) in patients with major depressive disorder (MDD) who have a partial response to ADT.

Clinical Trial Conditions for Rapastinel

Condition Name

Condition Name
Intervention	Trials
Depressive Disorder, Major	11
Major Depressive Disorder	1
Obsessive-Compulsive Disorder (OCD)	1
Driving Performance	1

Condition MeSH

Condition MeSH
Intervention	Trials
Depressive Disorder, Major	12
Depressive Disorder	12
Depression	12
Disease	11

Clinical Trial Locations for Rapastinel

Trials by Country

+

−

Trials by Country
Location	Trials
United States	220
Canada	4
Poland	2
Ukraine	2
Japan	2

Trials by US State

+

−

Trials by US State
Location	Trials
New York	11
California	11
Massachusetts	9
Illinois	9
Texas	9

Clinical Trial Progress for Rapastinel

Clinical Trial Phase

Clinical Trial Phase
Clinical Trial Phase	Trials
Phase 3	10
Phase 2	3
Phase 1	2

Clinical Trial Status

Clinical Trial Status
Clinical Trial Phase	Trials
Completed	8
Terminated	6
Withdrawn	1

Clinical Trial Sponsors for Rapastinel

Sponsor Name

Sponsor Name
Sponsor	Trials
Naurex, Inc, an affiliate of Allergan plc	14
Allergan	6
New York State Psychiatric Institute	1

Sponsor Type

Sponsor Type
Sponsor	Trials
Industry	21
Other	1